Introduction/Background
Increasing vaccination rates to reduce infectious diseases remains one of the Healthy People 2020 objectives set forth by the United States Office of Disease Prevention and Health Promotion. 1, 2 Vaccine innovation and increased vaccination rates were linked with increased survival in the 20 th century. However, certain infectious diseases that can be prevented by vaccines, still remain a major cause of morbidity and mortality. 2 Currently there are 17 vaccine-preventable diseases in the United States 1 , including influenza. Although preventable, influenza is one of the leading infections in the United States and accounts for substantial spending on the consequences associated with the virus. 2 Vaccines remain the most cost-effective intervention in clinical prevention of infectious disease and their proper use is essential. 2 Specifically, children's vaccination programs yield a higher return on investment.
Children receiving their vaccinations according to the CDC schedule saves 33,000 lives, prevents 14 million instances of disease, reduces health care cost by $9.9 billion, and saves $33.4 billion in indirect cost. In spite of the available vaccines, about 42,000 of adults and 300 children die each year from vaccine preventable diseases. 2 The pharmacists' role as vaccinators dates back to the 1800's. The first organized formal vaccination training for pharmacists A pharmacist offers significant clinical and financial benefits through vaccination services. Administering vaccines in a community pharmacy has become accepted by the public, especially for influenza vaccine. Commercial and governmental health plans are beginning to provide coverage for those patients receiving vaccinations at pharmacy locations. However, health plans stipulate vaccine coverage and may not always pay for all recommended vaccines. 6 The aim of this study is to review literature where the pharmacist as a vaccinator, has been financially and clinically assessed.
Objectives
The objectives for this review were to examine studies where the pharmacists served as a vaccinator and to document the clinical and financial impacts.
Methods
A broad literature search was conducted to identify economic and clinical data on pharmacists vaccinating in pharmacies. MEDLINE ® , PUBMED, NIH, and CDC databases were searched for publications useful or potentially useful in this collection of data. Search terms included vaccination, pharmacist, economic, pharmacoeconomics, cost, benefits cost-effectiveness, physicians, immunizations, vaccinations, pharmacy vaccines, cost, physician vaccines, financial, benefit, ambulatory pharmacist vaccination, clinical pharmacist, economics, pharmacist vaccine impact. Articles found were examined for relevance and a data table was created outlining areas where additional research is needed.
Results
The data examined in the literature review can be found in Tables 1 and 2 . The following are modified key points from the original article.
Vaccinations Administered During Off-Clinic Hours at a National Community Pharmacy: Implications for Increasing Patient Access and Convenience: 7  Researchers retrospectively reviewed data for all vaccinations administered at Walgreens pharmacies between August 2011 and July 2012. Specifically comparing between two time periods (standard clinic hours [9:00 am -6:00 pm] and off-clinic hours), they analyzed the type of vaccine given as well as patient populations in order to assess implications for access and convenience.  The following groups were most likely to be vaccinated during off-clinic hours: younger patients, patients living in metropolitan/micropolitan areas, patients living in states that allow pharmacists to administer all CDC-recommended vaccines, those receiving travel vaccines, and patients who receive > 2 vaccines in one year; this study found no difference in off-clinic hour use in patients who used the pharmacy for only vaccination vs those who were also picking up prescription.  Vaccines with the greatest proportion administered during off-clinic hours were typhoid (41.5%), Tdap (34.5%), HPV (33.8%), varicella zoster (31.6%), influenza (31.5%), hepatitis (31.4%), and yellow fever (30.8%).  More than 1 million vaccinations took place during lunch hours (11:00 am to 1:00 pm) out of total vaccinated administered of 6,250,402.  The proportion vaccinated during off-clinic hours was similar for patients with or without chronic conditions.  More than 150,000 vaccinations occurred during the overnight hours of 10:00 pm to 9:00 am. Specifically, the "intervention clinic" had a full-time, board-certified ambulatory clinical pharmacist who provided vaccination education to provider and patients. The "comparison clinic" did not include pharmacy personnel to ensure appropriate use of vaccines.  After researchers reviewed 900 total randomized encounters from both clinics, 19 errors were found in the evaluation. With 2 errors identified in the comparison clinic and 17 from the "intervention clinic," the error rate was 0.28% and 2.7%, respectively (P = 0.0021).  Further research of pharmacist involvement in several areas of vaccine use is needed. This study did not include an economic evaluation of improved use of vaccines. Additional research investigating the economic implications of pharmacist integration into the primary care setting on vaccine use is also needed.  Missed opportunities were defined as vaccine doses due at date of encounter and not given. In the comparison clinic, 132 randomized encounters were found to have greater than or equal to one missed opportunity, compared with 46 randomized encounters in the intervention clinic (P<0.0001).  Hepatitis A vaccine and Hepatitis B vaccine were the most common vaccines associated with missed opportunities.
Costs of Adult Vaccination in Medical Settings and Pharmacies: An Observational Study:
17  The objective of this observational retrospective study was to compare the direct costs paid in different settings (i.e., physician offices, other medical settings, and pharmacies) for adult vaccinations of zoster, pneumococcal, and influenza.  The costs paid for vaccination-included costs associated with the vaccine product, administration, dispensing, and outpatient visit fees. Visit fees for medical settings were included only in those instances where vaccination was determined to be the trigger for the visit, i.e., the only service provided during the visit (≤2% of instances).  Patients' mean (SD) ages across settings were 65.8 (6.7) years for zoster vaccine, 58.2 (12.2) years for pneumococcal vaccine, and 51.4 (13.8) years for influenza vaccine. pneumococcal vaccine-$54.98 (9.72) (P < 0.05), influenza vaccine-21.57 (6.63) (P < 0.05).  The data may help payers and policymakers understand the economic value of adult vaccination in different settings, especially in pharmacies.  For all 3 vaccines, the costs paid were significantly lower in pharmacies than in either physician offices or other medical settings (P < 0.05).  For zoster vaccination, patients paid the least out-ofpocket at physician offices ($16.95 [43.85] , P < 0.05), whereas insurers paid the least at pharmacies ($145.72 [$38 .54], P < 0.05).  For both the pneumococcal and influenza vaccines, patients paid the least at pharmacies, while insurers paid the least in other medical settings, and the most at physician offices.  For zoster vaccination, patients paid the least out-ofpocket at physician offices, whereas insurers paid the least at pharmacies.  From the patient perspective, costs paid were lower in pharmacies than in other medical settings for all 3 vaccinations and lower than in physician offices for pneumococcal and influenza vaccines.  Researchers conducted telephone interviews with representatives from each setting in 2004 to understand the costs of vaccination delivery in nontraditional settings. They found that vaccination delivery cost less in the nontraditional settings ($17 in mass vaccination settings, $12 in pharmacies) compared with physician offices ($29). Additionally, they found that vaccination in nontraditional settings was projected to be cost saving for healthy adults aged ≥50 years and for high-risk adults of all ages.  Pharmacies had lower average direct costs paid per adult vaccination than physician offices and other medical settings-by 16%-26% and 11%-20%, respectively-when both health plan and enrollees' perspectives were considered.
Non-Traditional Settings for Influenza Vaccination of Adults: Costs And Cost Effectiveness:
18  Using detailed phone interviews, researchers evaluated the costs of influenza vaccination in nontraditional settings. Target age population included 18-49, 50-64, and ≥65 years with either high risk or low risk for influenza-related complications. Probability, direct costs, and opportunity costs were derived from primary data, unpublished and published sources.  The mean total cost (US$, year 2004 values) per vaccination, not including time cost, was estimated as $11.57 for pharmacies, $17.04 for mass vaccination clinics, and $28.67 at doctor's office.  The mean waiting time for mass vaccination and pharmacy clinics was 12 minutes for both; the doctors waiting time was over 1 hour.  The reported mean cost per vaccine dose ranged from $7.48 in the pharmacy setting to $9.24 in the doctor's office.  The patients' time, labor, and overhead cost were higher in scheduled doctor visits.
Discussion
Pharmacists administering vaccines has effectively lowered health care cost and increased vaccination rates. The data compiled in this review has revealed ways pharmacists have been using their practice to advance the promotion and administration of the CDC recommended vaccinations. Pharmacists offer education, advertising, and incentives to reach patient populations in need of vaccinations. Pharmacies also have various conveniences such as extended hours, shortened wait times, ease of access for medically underserved patients in urban and rural areas, and reduced vaccination costs. [9] [10] [11] [12] 15 With 93% of Americans living within 5 miles of a community pharmacy, community pharmacists are one of the most readily accessible health care professionals in the United States.
5
The clinical data collected has shown that pharmacy convenience and public trust as a vaccinator group is not a unique characteristic of pharmacists in the United States. 10, 11 Many patients in the UK preferred to pay the pharmacist for an influenza vaccination instead of receiving it for free from their general practitioner. 10, 11 Several studies demonstrate that many patients in the UK and United States go to the pharmacy during lunch hours. 7, 10, 11 Convenience is arguably the most advantageous characteristic of pharmacies as a vaccination location. In addition, many pharmacies are open 24 hours including holidays, allowing patients to receive vaccinations during these off-clinic hours.
7
Despite the convenience, various barriers such as state laws, collaboration protocols, and health plan restrictions further prevent pharmacies from administering the full CDC recommend schedule. An estimated 40,000 to 50,000 adults die annually from vaccine-preventable disease in the United States.
5 Additionally, $10 billion dollars are used to treat patients without routine or recommended vaccinations. 5 The state laws restricting pharmacists as a vaccinator are inconsistent and seemingly arbitrary ( Table 3) . Many state laws prevent pharmacists from providing vaccinations to the most cost-effective population-children. Some states limit the pharmacist to certain types of vaccines. The 2016 ACPE accreditation standards for the doctor of pharmacy curriculum requires pharmacy schools to provide training for students to become certified in administering injections. 21 Furthermore, biologics and vaccines are considered pharmaceutical products approved through the FDA, which positions pharmacists as vaccine experts. The expertise provided by pharmacists was demonstrated in Haas-gehres a, et al. where pharmacy interventions significantly decreased missed opportunities for scheduled vaccinations. 16 Vaccination protocols, prescription only orders and standing orders are additional barriers to patient access to pharmacy service. Also, both commercial and state health plans do not readily cover all scheduled vaccines 5 when administered in the pharmacy setting, further hindering healthcare. With the inconsistent restrictions and lack of medical standard, research concerning protocols and orders would assist in determining the practicality of these restrictions.
Economically, vaccines delivered in the pharmacy lower the cost for health care. 17, 18 Patients have higher direct and opportunity costs when getting vaccinations at their physician's office. 18, 19 A recent study has shown the average opportunity cost per physician visit was $43, which exceeds the average patient's out-of-pocket payment. Total opportunity costs per year for all physician visits in the United States were $52 billion in 2010. 19 Studies have shown that receiving vaccines in the pharmacy setting was the least expensive option for patients. In contrast, vaccines delivered in the traditional physical office setting are the most expensive. 17, 18 The patient may also experience opportunity costs due to office wait times or appointment co-pays. [17] [18] [19] Compounding the inconveniences of going to a physician office has made many patients appreciate the prompt service in the pharmacy setting. Additional electronic technologies within pharmacy software systems have enabled pharmacists to identify risk groups in need of vaccinations. Researchers have conducted a study using claims data as an identifying tool.
14 Moreover, patients visit their pharmacies more frequently, thus facilitating the verification of vaccine history and minimizing missed opportunities.
After reviewing the literature, pharmacy practice should enhance the pharmacist's role as a vaccinator by including complete vaccination records with the patient's medication profile. The community pharmacy serves as a valuable source of history for each patient's prescriptions records, and adding the vaccination history to the patient profile will help identify those who have not received their recommended vaccinations according to the CDC guidelines. The vaccination history developed by the pharmacist will also serve as a tool to assist various medical personnel involved with the patient. Also, insurance companies should extend pharmacy insurance benefits to cover vaccines as a preventative pharmaceutical measure against disease. Expanding vaccines coverage in the pharmacy setting will bring current those who are irregularly vaccinated and increase vaccination rates in hard-to-reach populations.
12
The following are research proposals that can measure the clinical and economic impact of the pharmacist as a vaccinator: comparisons of direct cost and opportunity cost for the full vaccination schedule administered at the community pharmacy vs. the physician's office, cost effectiveness of travel vaccines given in a community pharmacy setting, a study to determine or estimate the average number of vaccinations a pharmacy administers annually, an observational claims analysis of rejected vaccinations by an insurance provider in the community setting, and a literature review of pharmacy protocols and state law limitations.
Conclusion
Pharmacists as vaccinators are an underutilized vaccine provider source. This literature review reveals a pattern among studies measuring pharmacists' impact on vaccine rates, patient preferences, and cost savings. Expanding the pharmacists' ability to vaccinate more population groups through the changing legislation has traditionally increased vaccination rates by state.
13 Inconsistency exists within the health benefits system, which complicates pharmacy vaccination efforts. Vaccination is the most cost effective way to prevent infectious disease and comorbid complications, however commercial and governmental health plans provide limited coverage for receiving vaccinations from a pharmacy.
5
Pharmacists have demonstrated to be dependable, accurate, and cost effective vaccination providers. State laws, collaborate agreement protocols, and health plans have prevented patients from using the pharmacy to receive all CDC recommended vaccines which can potentially delay the Healthy People 2020 goal of increasing vaccination rates and reducing preventable infectious diseases. Van amburgh JA et al. Pharmacotherapy. 2001; 21(9):1115-22 . 900 encounters were randomly selected and reviewed. The error rate was found to be 0.28% in the intervention clinic and 2.7% in the comparison clinic. The difference in error rates was found to be significant (P = 0.0021). The number of encounters with greater than or equal to one missed opportunity was significantly higher in the comparison clinic compared with the intervention clinic (29.3% vs. 10.2%; P <0.0001).
Pharmacist have the ability to identify CDC scheduled recommendation in pediatric population.
Pharmacist can support ambulatory clinics to increase vaccination rates and decreases the rates of missed opportunities. For all 3 vaccines, the costs paid were significantly lower in pharmacies than in either physician offices or other medical settings (P < 0.05).
The mean amounts paid also differed by geographic region and type of health plan, with costs usually lower for the vaccinations given at pharmacies.
The average direct costs paid per adult vaccination were lower in pharmacies compared with physician offices and other medical settings by 16%-26% and 11%-20%, respectively.
These results were mostly consistent across geographic regions and types of health plans.
These data may help payers and policymakers understand the economic value of adult vaccination in different settings, especially in pharmacies.
The data may also help medical or pharmacy insurance providers understand the economic value of expanding the vaccination schedule coverage to the pharmacy setting. 
